PMP22 and Charcot-Marie-Tooth disease type 1A: Non-viral gene therapies are also being developed for CMT1A including a subcutaneous injection of ASOs, an intravenous injection of siRNA encapsulated by squalenoyl nanoparticles, and an intra-nerve injection of CRISPR/Cas9 targeting the super enhancer in the PMP22 promoter which all remain under preclinical evaluation [198].